Immunotherapy in colorectal cancer: For the select few or all?

Sukeshi Patel Arora*, Devalingam Mahalingam

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

44 Scopus citations


Over the past few years, the role of immunotherapy in colorectal cancer (CRC) has expanded, specifically in subsets of CRC with microsatellite instability (MSI) for which newer agents, such as programmed death-1 (PD-1) inhibitors, are efficacious. While other immunotherapeutic agents are more immature in development, they have the potential to enhance the efficacy of PD-1 inhibitors and play a role in the treatment algorithm for all subsets of CRC patients. In this review, we will discuss immunotherapeutic agents in development in patients with CRC. We will review the later phase studies that elucidate the role of immunotherapy in CRC and provide hope for changing the treatment paradigm for CRC in the future.

Original languageEnglish (US)
Pages (from-to)170-179
Number of pages10
JournalJournal of Gastrointestinal Oncology
Issue number1
StatePublished - Feb 1 2018


  • Checkpoint inhibition
  • Colorectal cancer (CRC)
  • Immunotherapy
  • Mismatch repair
  • Programmed death-1 (PD-1)

ASJC Scopus subject areas

  • Gastroenterology
  • Oncology


Dive into the research topics of 'Immunotherapy in colorectal cancer: For the select few or all?'. Together they form a unique fingerprint.

Cite this